The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Theron, Grant ^a   Peter, Jonny ^a   Richardson, Marty ^b   Barnard, Marinus ^c   Donegan, Sarah ^b   Warren, Rob ^c   Steingart, Karen R ^b   Dheda, Keertan ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE SEQUENCE; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUBERCULOSIS; ADULT; CROSS-SECTIONAL STUDY; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; META ANALYSIS; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; STANDARDS;

ADULT; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84965185122     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010705.pub2     Document Type: Review

References (69)

1. Ajbani K, Nikam C, Kazi M, Gray C, Boehme C, Balan K, et al.Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments. PLoS One 2012;7(11):e49433.
2. Barnard M, Warren R, Gey Van Pittius N, van Helden P, Bosman M, Streicher E, et al.Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. American Journal of Respiratory and Critical Care Medicine 2012;186(12):1298-305.
3. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. Journal of Clinical Microbiology 2010;48(5):1683-9.
4. Chikamatsu K, Aono A, Yamada H, Mitarai S. Evaluation of GenoType MTBDRsl for testing resistance of Mycobacterium tuberculosis isolates to fluoroquinlone, aminoglycoside, and ethambutol. Kekkaku (Tuberculosis) 2012;87(10):641-7.
5. Fan QW, Guo J, Zhang HZ, Wu XY, Hu XN, Qian XQ, et al.The characteristics of drug resistant relevant genes in multidrug-resistant and extensively drug-resistant tuberculosis by fast molecular assay [Chinese]. Chinese Journal of Microbiology and Immunology 2011;31(12):1133-7.
6. Ferro B, García P, Nieto LM, van Soolingen D. Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. Journal of Clinical Microbiology 2013;51(7):2220-4.
7. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of Clinical Microbiology 2009;47(6):1767-72.
8. Huang WL, Chi TL, Wu MH, Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. Journal of Clinical Microbiology 2011;49(7):2502-8.
9. Ignatyeva O, Kontsevaya I, Kovalyov A, Balabanova Y, Nikolayevskyy V, Toit K, et al.Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multi-center evaluation and feasibility study. Journal of Clinical Microbiology 2012;50(5):1593-7.
10. Jin J, Shen Y, Fan X, Diao N, Wang F, Wang S, et al.Underestimation of the resistance of Mycobacterium tuberculosis to second-line drugs by the new GenoType MTBDRsl test. Journal of Molecular Diagnostics 2013;15(1):44-50.
11. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, van Vinh Chau N, et al.Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology 2010;48(8):2934-9.
12. Kontsevaya I, Mironova S, Nikolayevskyy V, Balabanova Y, Mitchell S, Drobniewski F. Evaluation of two molecular assays for rapid detection of Mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance settings. Journal of Clinical Microbiology 2011;49(8):2832-7.
13. Kontsevaya I, Ignatyeva O, Nikolayevskyy V, Balabanova Y, Kovalyov A, Kritsky A, et al.Rapid diagnosis of extensively-drug resistant TB in HIV co-infected patients: diagnostic accuracy of the GenoType(R) MTBDRsl assay. Journal of Clinical Microbiology 2013;51(1):243-8.
14. Lacoma A, García-Sierra N, Prat C, Maldonado J, Ruiz-Manzano J, Haba L, et al.GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. Journal of Clinical Microbiology 2012;50(1):30-6.
15. López-Roa P, Ruiz-Serrano MJ, Alcalá L, García-Escribano Ráez N, García de Viedma D, Bouza E. Susceptibility testing to second-line drugs and ethambutol by GenoType MTBDRsl and Bactec MGIT 960 comparing with agar proportion method. Tuberculosis 2012;92(5):417-21.
16. Miotto P, Cabibbe AM, Mantegani P, Borroni E, Fattorini L, Tortoli E, et al.GenoType MTBDRsl performance on clinical samples with diverse genetic background. European Respiratory Journal 2012;40(3):690-8.
17. Said HM, Kock MM, Ismail NA, Baba K, Omar SV, Osman AG, et al.Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. International Journal of Tuberculosis and Lung Disease 2012;16(1):104-9.
18. Surcouf C, Heng S, Pierre-Audigier C, Cadet-Daniel V, Namouchi A, Murray A, et al.Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes. BMC Infectious Diseases 2011;11:255-62.
19. Tukvadze N, Bablishvili N, Apsindzelashvili R, Blumberg HM, Kempker RR. Performance of the MTBDRsl assay in Georgia. International Journal of Tuberculosis and Lung Disease 2014;18(2):233-9.
20. van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, Boeree MJ, et al.Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. Journal of Clinical Microbiology 2010;48(8):2749-53.
21. Živanović I, Vuković D, Dakić I, Stefanović G, Savić B. Detection of drug-resistant Mycobacterium tuberculosis strains isolated in Serbia by the GenoType MTBDRsl assay. Archives of Biological Sciences 2012;64(4):1311-8.
22. Bantouna V, Kontos F, Gitti Z, Spandidos DA. Evaluation of the new GenoType MTBDRs1 (R) assay for rapid detection of resistance in Mycobacterium tuberculosis isolates at a low-incidence community. International Journal of Molecular Medicine. 2011; Vol. 28:S76.
23. Bergvala L, Sengstakea S, Bachyiska E, Brankova N, Tankova K, Levterova V, et al.Evaluation of a new molecular test for the identification of drug resistance in Mycobacterium tuberculosis clinical isolates. Problems of Infectious and Parasitic Diseases 2010;38(2):27-30.
24. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by genotype MTBDRsl test of complex resistance mechanisms to second-line drugs and ethambutol in multidrug-resistant strains of Mycobacterium tuberculosis. Journal of Clinical Microbiology 2010;48(5):1683-9.
25. Choi JH, Lee KW, Kang HR, Hwang YI, Jang S, Kim DG, et al.Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest 2010;137(2):393-400.
26. Fallico L, Peracchi M, Khalil S, Rassu M, Pascarella M, Manganelli R, et al.Molecular epidemiology and prevalence of mutations in Mycobacterium tuberculosis strains from an Italian northeastern area. Clinical Microbiology and Infection. 2012; Vol. 18:550.
27. Felkel M, Exner R, Schleucher R, Lay H, Autenrieth I, Kempf VA, et al.Evaluation Of Mycobacterium tuberculosis drug susceptibility in clinical specimens from Nigeria using Genotype MTBDRplus and MTBDRsl assays. European Journal of Microbiology and Immunology 2013;3(4):252-7.
28. Festoso I, Mantegani P, Miotto P, Cabibbe AM, Valente I, Borroni E, et al.Clinical evaluation of the GenoType MTBDRsl for the rapid diagnosis of second-line resistance in Mycobacterium tuberculosis. Clinical Microbiology and Infection. 2011; Vol. 17:S592.
29. Gkaravela L, Foka A, Athanassiou M, Lazarou N, Kontos F, Mollaki V, et al.The genetic diversity of Mycobacterium tuberculosis complex in Azerbaijan by 24 MIRU-VNTR loci genotyping in association with susceptibility testing by conventional and molecular methods. Clinical Microbiology and Infection. 2012; Vol. 18:829.
30. Iem V, Somphavong S, Buisson Y, Steenkeste N, Breysse F, Chomarat M, et al.Resistance of Mycobacterium tuberculosis to antibiotics in Lao PDR: first multicentric study conducted in 3 hospitals. BMC Infectious Diseases 2013;13:275.
31. Jang E, Hwang S, Ryoo S. Practical value of the Genotype MTBDRsl assay for XDR testing of Mycobacterium tuberculosis from clinical isolates. American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS. 2011; Vol. 183.
32. Karabela S, Nikolaou S, Kouseris I, Makrigiannis N, Kanavaki S. Extensively drug-resistant tuberculosis (XDR TB) in Athens. International Journal of Antimicrobial Agents. 2007; Vol. 29 (Suppl 2):S574.
33. Kontos F, Zande M, Mavromanolakis D, Bazigos S, Manidaki A, Gitti Z. Evaluation of the new GenoType MTBDRsl assay for rapid detection of resistance in Mycobacterium tuberculosis isolates in a low-incidence community. Clinical Microbiology and Infection. 2011; Vol. 17:S587.
34. Kontos F, Bobola M, Mollaki V, Karonis T, Souli M, Dimopoulos G, et al.Tuberculosis: molecular susceptibility testing reveals mixed infections with three strains. Clinical Microbiology and Infection. 2012; Vol. 18:553-4.
35. Lemus D, Alvarez Y, Díaz R, Valdés I, Echemendía M, Martin A, et al.Molecular confirmation of resistance to first- and second-line antituberculosis drugs using GenoType MTBDRplus and GenoType MTBDRsl assays. Clinical Microbiology and Infection. 2011; Vol. 17:S729.
36. López Roa P, Ruiz-Serrano MJ, García-Escribano N, García de Viedma D, Bouza E. Rapid testing of susceptibility of multidrug-resistant Mycobacterium tuberculosis (MDRTB) to second-line drugs using GenoType MTBDRsl. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2010; Vol. 50.
37. ® MTBDRsl assay. Journal of Postgraduate Medicine 2013;59(3):179-85.
38. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infectious Diseases 2012;12:37.
39. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia. International Journal of Tuberculosis and Lung Disease 2012;16(6):805-11.
40. Totten S, May R, Heifets LB. Comparative study of two diagnostic tools for the rapid detection of Mycobacterium tuberculosis complex from smear positive respiratory specimens. American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS. 2011; Vol. 183:A4889.
41. Zhang L, Duo L, Lu X, Xie Y, Song X, Kang M, et al.Molecular epidemiology of multidrug-resistant (MDR) Mycobacterium tuberculosis revealed by GenoType MTBDR assays in southern China. Clinical Microbiology and Infection. 2011; Vol. 17:S599-600.
42. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, et al.Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007;370(9597):1500-7.
43. Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, Gandhi NR, et al.Averting epidemics of extensively drug-resistant tuberculosis. Proceedings of the National Academy of Sciences of the United States of America 2009;106(18):7672-7.
44. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al.Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375(9728):1798-807.
45. Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infectious Disease Clinics of North America 2010;24(3):705-25.
46. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proceedings of the National Academy of Sciences of the United States of America 2008;105(32):11293-8.
47. Feng Y, Liu S, Wang Q, Wang L, Tang S, Wang J, et al.Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS One 2013;8(2):e55292.
48. Georghiou S, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell T. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012;7(3):e33275.
49. Hain Life Sciences. Genotype MTBDRsl product information sheet Version 2.0. http://www.tbevidence.org/documents/rescentre/sop/MTBDRsl.pdf (accessed 02 July 2012):1-16.
50. Hain LIfe Sciences. Genotype MTBDRsl product information sheet Version 2.0. http://www.hain-lifescience.co.za/products/microbiology/mycobacteria/genotype-mtbdrsl.html (accessed 02 July 2012):1-16.
51. Heysell SK, Houpt ER. The future of molecular diagnostics for drug-resistant tuberculosis. Expert Review of Molecular Diagnostics 2012;12(4):395-405.
52. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and presenting results In: Deeks JJ, Bossuyt PM, Gatsonis C (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: http://srdta.cochrane.org/.
53. Menzies D. Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Infection Control and Hospital Epidemiology 1997;18(8):582-6.
54. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?. PLoS One 2013;8(1):e54587.
55. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982-90.
56. The Nordic Cochrane Centre, The Cochane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochane Collaboration, 2012.
57. Richter E, Rüsch-Gerdes S, Hillemann D. Drug-susceptibility testing in TB: current status and future prospects. Expert Review of Respiratory Medicine 2009;3(5):497-510.
58. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy 2012;67(5):1088-93.
59. Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, van Helden PD, et al.Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microbial Drug Resistance 2012;18(2):193-7.
60. Streicher EM, Müller B, Chihota V, Mlambo C, Tait M, Pillay M, et al.Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infection, Genetics and Evolution 2011;12(4):686-94.
61. Tatsioni A, Zarin DA, Aronson N, Samson DJ, Flamm CR, Schmid C, et al.Challenges in systematic reviews of diagnostic technologies. Annals of Internal Medicine 2005;142(12 Pt 2):1048-55.
62. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Medical Research Methodology 2005;5(19):1-9.
63. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
64. World Health Organization. Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Summary report of the Expert Group Meeting on the use of liquid culture media, Geneva, 26 March 2007. http://www.who.int/tb/laboratory/use_of_liquid_tb_culture_summary_report.pdf (accessed 15 August 2014).
65. World Health Organization. Global tuberculosis report 2013. http://www.who.int/tb/publications/global_report/en/ (accessed 15 August 2014):1-100.
66. World Health Organization, StopTB Working Group. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. Expert group meeting report, Geneva: February 2013. http://apps.who.int/iris/bitstream/10665/78099/1/WHO_HTM_TB_2013.01.eng.pdf (accessed 12 June 2014).
67. World Bank. World Bank list of economies (February 2014). Washington (District of Columbia) (accessed 1 February 2014).
68. Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Medical Research Methodology 2006;6:31.
69. Zhao Y, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, et al.National survey of drug-resistant tuberculosis in China. New England Journal of Medicine 2012;366(23):2161-70.